Royal London Asset Management’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $11.8M | Sell |
64,266
-299
| -0.5% | -$55.1K | 0.02% | 427 |
|
|
2025
Q4 | $11.4M | Sell |
64,565
-1,406
| -2% | -$230K | 0.02% | 423 |
|
|
2025
Q3 | $9.24M | Sell |
65,971
-1,775
| -3% | -$240K | 0.02% | 458 |
|
|
2025
Q2 | $8.51M | Sell |
67,746
-2,494
| -4% | -$311K | 0.02% | 466 |
|
|
2025
Q1 | $9.61M | Buy |
70,240
+5,283
| +8% | +$755K | 0.02% | 446 |
|
|
2024
Q4 | $9.93M | Sell |
64,957
-672
| -1% | -$113K | 0.02% | 425 |
|
|
2024
Q3 | $12.7M | Sell |
65,629
-3,943
| -6% | -$825K | 0.03% | 379 |
|
|
2024
Q2 | $16.1M | Buy |
69,572
+12,751
| +22% | +$2.77M | 0.04% | 315 |
|
|
2024
Q1 | $12.3M | Sell |
56,821
-394
| -0.7% | -$92.3K | 0.03% | 362 |
|
|
2023
Q4 | $14.8M | Sell |
57,215
-3,520
| -6% | -$865K | 0.04% | 315 |
|
|
2023
Q3 | $15.6M | Sell |
60,735
-9,495
| -14% | -$2.54M | 0.05% | 279 |
|
|
2023
Q2 | $20M | Sell |
70,230
-26,145
| -27% | -$7.78M | 0.06% | 235 |
|
|
2023
Q1 | $26.8M | Sell |
96,375
-44,443
| -32% | -$12.3M | 0.11% | 162 |
|
|
2022
Q4 | $39M | Sell |
140,818
-14,693
| -9% | -$4.15M | 0.17% | 118 |
|
|
2022
Q3 | $41.5M | Buy |
155,511
+51,613
| +50% | +$11M | 0.21% | 92 |
|
|
2022
Q2 | $21.2M | Sell |
103,898
-863
| -0.8% | -$176K | 0.1% | 177 |
|
|
2022
Q1 | $22.1M | Buy |
104,761
+3,827
| +4% | +$832K | 0.09% | 192 |
|
|
2021
Q4 | $24.2M | Sell |
100,934
-6,572
| -6% | -$1.69M | 0.09% | 178 |
|
|
2021
Q3 | $30.4M | Sell |
107,506
-3,472
| -3% | -$1.14M | 0.12% | 150 |
|
|
2021
Q2 | $38.5M | Sell |
110,978
-6,069
| -5% | -$1.84M | 0.16% | 127 |
|
|
2021
Q1 | $32.8M | Buy |
117,047
+3,975
| +4% | +$1.07M | 0.15% | 135 |
|
|
2020
Q4 | $27.7M | Buy |
113,072
+2,017
| +2% | +$520K | 0.15% | 138 |
|
|
2020
Q3 | $31.4M | Sell |
111,055
-1,977
| -2% | -$551K | 0.19% | 108 |
|
|
2020
Q2 | $29.4M | Sell |
113,032
-8,474
| -7% | -$2.55M | 0.21% | 107 |
|
|
2020
Q1 | $38.4M | Buy |
121,506
+2,015
| +2% | +$611K | 0.31% | 77 |
|
|
2019
Q4 | $35.4M | Sell |
119,491
-2,412
| -2% | -$669K | 0.24% | 96 |
|
|
2019
Q3 | $28.4M | Sell |
121,903
-986
| -0.8% | -$230K | 0.22% | 109 |
|
|
2019
Q2 | $28.7M | Sell |
122,889
-1,229
| -1% | -$284K | 0.27% | 90 |
|
|
2019
Q1 | $29.3M | Buy |
124,118
+9,382
| +8% | +$2.95M | 0.23% | 104 |
|
|
2018
Q4 | $33.7M | Buy |
114,736
+26,068
| +29% | +$8.32M | 0.29% | 81 |
|
|
2018
Q3 | $31.3M | Sell |
88,668
-2,702
| -3% | -$930K | 0.32% | 74 |
|
|
2018
Q2 | $26.5M | Buy |
+91,370
| New | +$25.7M | 0.27% | 87 |
|
|
2016
Q2 | $17.9M | Sell |
73,955
-14,111,275
| -99% | -$3.72B | 0.29% | 79 |
|
|
2016
Q1 | $54K | Buy |
14,185,230
+14,105,220
| +17,629% | +$3.73B | 0.08% | 285 |
|
|
2015
Q4 | $24.7M | Sell |
80,010
-3,992
| -5% | -$1.15M | 0.38% | 61 |
|
|
2015
Q3 | $24.5M | Buy |
+84,002
| New | +$27.7M | 0.4% | 58 |
|
|
2014
Q4 | $255K | Buy |
74,491
+16,472
| +28% | +$5.33M | 0.48% | 49 |
|
|
2014
Q3 | $19.2M | Buy |
58,019
+3,028
| +6% | +$998K | 0.48% | 45 |
|
|
2014
Q2 | $17.9M | Sell |
54,991
-246
| -0.4% | -$74K | 0.41% | 58 |
|
|
2014
Q1 | $16.6M | Sell |
55,237
-1,594
| -3% | -$506K | 0.39% | 65 |
|
|
2013
Q4 | $17M | Buy |
56,831
+1,736
| +3% | +$449K | 0.43% | 54 |
|
|
2013
Q3 | $13.7M | Buy |
55,095
+736
| +1% | +$165K | 0.37% | 61 |
|
|
2013
Q2 | $11.4M | Buy |
+54,359
| New | +$11.6M | 0.33% | 70 |
|
Other funds holding BIIB
VCM
VPM
Royal London Asset Management's BIIB Position: Q1 2026 in Review
Royal London Asset Management reduced its Biogen (BIIB) stake by 0.46% in Q1 2026, selling an estimated $55.1K and leaving 64,266 shares worth $11.8M. The position accounts for 0.02% of the portfolio, ranked #427.
Royal London Asset Management first reported a position in BIIB in Q2 2013 and has held it in 43 quarters since. The position peaked at $41.5M in Q3 2022. 1,008 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.
- Royal London Asset Management held 64,266 shares of Biogen worth $11.8M as of Q1 2026.
- Royal London Asset Management sold 299 Biogen shares in Q1 2026, an estimated $55.1K.
- Biogen made up 0.02% of Royal London Asset Management's portfolio in Q1 2026, its #427 holding.
- Royal London Asset Management first reported a position in Biogen in Q2 2013 and has held it in 43 quarters since.
- Royal London Asset Management's Biogen position peaked at $41.5M in Q3 2022.
- 1,008 funds tracked by Wall St. Rank held Biogen as of Q1 2026.
Based on Royal London Asset Management's 13F filing for Q1 2026, filed 1 May 2026.